Skip to main content

Medication Treatments

New research involving Massachusetts patients receiving buprenorphine for opioid use disorder shows increased overdose risk but greater treatment engagement with concurrent use of a benzodiazepine.
A cohort study has reported that a group receiving the longest duration of buprenorphine treatment had fewer hospitalizations and filled opioid prescriptions post-treatment.
An analysis of opioid use disorder treatment under Medicaid in North Carolina finds that while more patients are receiving evidence-based care, the service gap continues to widen.
Community Medical Services regional operations manager Haley Horton explained to NCAD West attendees how the organization has engaged patients in remote areas through the development of medication units as a complement to its traditional opioid treatment programs.
A life sciences company that is testing a sustained-release risperidone product for psychosis is now pursuing an effort to improve adherence to naltrexone for opioid dependence.
Back to Top